Johns Hopkins Arthritis Center

Home / Arthritis News / FDA Advisory Panel Finds Leflunomides Safety is Adequate

FDA Advisory Panel Finds Leflunomides Safety is Adequate

By


FDA Advisory Panel Finds Leflunomides Safety is Adequate

In response to concerns over the rheumatoid arthritis (RA) drug leflunomide (Arava®), the FDA appointed an advisory panel of experts to review data and determine if the safety risks of leflunomide were acceptable. In a 20-0 vote, the panel has agreed that leflunomides safety is adequate and acceptable. Based on evidence to date, the panel believes that the benefits of leflunomide outweigh the potential safety risks. Additionally, the panel supports the approval of a new indication for leflunomide, that being the improvement physical function in patients with RA.

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.